Long-Term Follow-Up of Patients With Positive Antiphospholipid Antibodies After Fetal Death: Five Typical Cases From a Prospective Cohort Study

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2025 Feb 13

PMID 39945244

Authors

Anxia Xie

Zhanmei Liu

Shenglan Wang

Mingqian Yuan

Ling Xie

Shengdong Liu

Xiaoxing Wei

Affiliations

Soon will be listed here.

Abstract

Background: Testing of antiphospholipid antibodies (aPLs) has attracted increasing attention for its association with thrombosis and pregnancy loss. However, few studies reported long-term monitoring outcomes of patients who experienced pregnancy loss and exhibited positivity for aPLs.

Objective: We investigated the causes of fetal death in five cases with positive aPLs and traced the patients for changes in aPLs, subsequent pregnancy outcomes, and thrombotic events.

Methods: This is a report of five typical cases from a prospective cohort study on the diagnosis of antiphospholipid syndrome (APS) in patients who were hospitalized for fetal death in Xining, China. Long-term follow-up was conducted and repeat aPL testing was recommended when the patients were confirmed or suspect APS.

Results: All five patients had subsequent pregnancies that resulted in term livebirths. None of the patients experienced thrombotic events. One showed progression of aPL serostatus from alone IgM of aβ2GP-1 to both IgM and IgG of aβ2GP-1, two exhibited fluctuation of aPL serostatus, and one had negative conversion, and the other one had not retested aPLs and did not receive any intervention with uneventful subsequent pregnancy.

Conclusions: The aPLs of a patient with APS may develop or may disappear, so long-term monitoring cannot be discounted. Also, a woman who has experienced fetal death and exhibits positivity for aPLs may not necessarily be a patient with APS, as there are a variety of conditions in which aPLs appear.

References

Allen K, Fonseca F, Betapudi V, Willard B, Zhang J, McCrae K . A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood. 2011; 119(3):884-93. PMC: 3265208. DOI: 10.1182/blood-2011-03-344671. View

Medina G, Briones-Garcia E, Cruz-Dominguez M, Florez-Durante O, Jara L . Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence. Autoimmun Rev. 2017; 16(4):352-354. DOI: 10.1016/j.autrev.2017.02.004. View

Garcia D, Erkan D . Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018; 378(21):2010-2021. DOI: 10.1056/NEJMra1705454. View

Kovacs M, Lazo-Langner A, Kovacs M . Long term monitoring of patients with positive lupus anticoagulant and antiphospholipid antibodies. Are all cases persistently positive?. Thromb Res. 2020; 194:119-120. DOI: 10.1016/j.thromres.2020.06.031. View

Kelchtermans H, Pelkmans L, de Laat B, Devreese K . IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost. 2016; 14(8):1530-48. DOI: 10.1111/jth.13379. View

Yelnik C, Porter T, Branch D, Laskin C, Merrill J, Guerra M . Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis Rheumatol. 2016; 68(8):1964-9. PMC: 5380363. DOI: 10.1002/art.39668. View

Espinosa G, Cervera R . Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol. 2010; 6(5):296-300. DOI: 10.1038/nrrheum.2010.47. View

Rambaldi M, Mecacci F, Guaschino S, Paidas M . Inherited and acquired thrombophilias. Reprod Sci. 2013; 21(2):167-82. DOI: 10.1177/1933719113497282. View

Nelen W . Hyperhomocysteinaemia and human reproduction. Clin Chem Lab Med. 2001; 39(8):758-63. DOI: 10.1515/CCLM.2001.126. View

10.

Knight J, Branch D, Ortel T . Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023; 380:e069717. DOI: 10.1136/bmj-2021-069717. View

11.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W . Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17):e38. PMC: 7161262. DOI: 10.1056/NEJMc2007575. View

12.

Ambrosino P, Lupoli R, Tarantino P, Di Minno A, Tarantino L, Di Minno M . Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis. Dig Liver Dis. 2015; 47(6):478-87. DOI: 10.1016/j.dld.2015.03.006. View

13.

Casais P, Meschengieser S, Gennari L, Alberto M, Sanchez-Luceros A, Blanco A . Antiphospholipid antibodies and hyperhomocysteinaemia in patients with vascular occlusive disease. Thromb Haemost. 2006; 96(1):19-23. DOI: 10.1160/TH05-11-0737. View

14.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

15.

Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo M . 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023; 82(10):1258-1270. DOI: 10.1136/ard-2023-224609. View

16.

Abdel-Wahab N, Talathi S, Lopez-Olivo M, Suarez-Almazor M . Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2017; 27(4):572-583. DOI: 10.1177/0961203317731532. View